|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2904011 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13774596.4 |
| Date of filing the European patent application | 2013-10-02 | |
| (97) | Date of publication of the European application | 2015-08-12 |
| (45) | Date of publication and mention of the grant of the patent | 2017-08-23 |
| (46) | Date of publication of the claims translation | 2017-11-10 |
| (86) | Number | PCT/US2013/063068 |
| Date | 2013-10-02 |
| (87) | Number | WO 2014/055648 |
| Date | 2014-04-10 |
| (30) | Number | Date | Country code |
| 201261708784 P | 2012-10-02 | US |
| (72) |
GRAZIANO, Robert, F., US
GUPTA, Ashok, K., US
KIM, Su, Young, US
WIGGINTON, Jon, US
|
| (73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Otilija KLIMAITIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Anti-KIR antikūnų ir anti-PD-1 antikūnų derinys, akirtas vėžio gydymui |
| COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT CANCER |
| Payment date | Validity (years) | Amount | |
| 2023-09-18 | 11 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-10-02 |